E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Homozygous Familial Hypercholesterolemia |
|
E.1.1.1 | Medical condition in easily understood language |
Hypercholesterolemia, specifically, elevated low density lipoprotein cholesterol (LDL-C), is one of the major risk factors for the development of coronary heart disease (CHD). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10057080 |
E.1.2 | Term | Homozygous familial hypercholesterolemia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize the effect of 90 and 180 days of subcutaneous ALN-PCSSC on the percentage change from Day 1 in low-density lipoprotein cholesterol (LDL-C) in subjects with homozygous familial hypercholesterolemia. |
|
E.2.2 | Secondary objectives of the trial |
– To assess the effect of ALN-PCSSC on: • Absolute change and percentage change in LDL-C from Day 1 to each subsequent visit until Day 180 or final visit • Absolute change and percentage change in PCSK9 • Absolute change and percentage change in total cholesterol, triglycerides, HDL-C, non-HDL-C, VLDL-C, Apo-A1, Apo-B and Lp(a) from Day 1 to each subsequent visit until Day 180 or final visit – To evaluate the safety and tolerability of ALN-PCSSC in subjects with homozygous familial hypercholesterolemia
Exploratory objectives: – To evaluate the formation of Anti-drug antibodies (ADA) to ALN- PCSSC – To assess response of LDL-C by underlying causal mutations of homozygous familial hypercholesterolemia (HoFH)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Males and females, ≥ 12 years of age with a diagnosis of homozygous familial hypercholesterolemia by genetic confirmation or a clinical diagnosis based on a history of an untreated LDL-C concentration >500 mg/dl (13 mmol/L) together with either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents. 2. Stable on a low-fat diet 3. Stable on their pre-existing, lipid-lowering therapies (such as statins, cholesterol-absorption inhibitors, bile-acid sequestrants, or combinations thereof) for at least 4 weeks with no planned medication or dose change for the duration of study participation 4. Fasting central lab LDL-C concentration >130 mg/dl (3.4 mmol/L) and triglyceride concentration < 400 mg/dL (4.5 mmol/L), 5. Bodyweight of 40 kg or greater at screening. 6. Subjects should be willing and able to give written informed consent before initiation of any study-related procedures (if the subject is less than 18 years of age, written consent will be obtained from their guardian or legally authorized representative, with verbal assent from the child). |
|
E.4 | Principal exclusion criteria |
1. LDL or plasma apheresis within 8 weeks prior to the screening visit, and no plan to receive it during the study because of the attendant difficulty in maintaining stable concentrations of LDL-C while receiving apheresis. 2. Use of Mipomersen or Lomitapide therapy within 5 months of screening. 3. Previous treatment with monoclonal antibodies directed towards PCSK9 within 8 weeks of screening. 4. New York Heart Association (NYHA) class III or IV heart failure or last known left ventricular ejection fraction < 30% or any cardiac arrhythmia within past 3 months that is not controlled by medication. 5. Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of enrollment 6. Planned cardiac surgery or revascularization 7. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg despite anti-hypertensive therapy. 8. Poorly controlled diabetes mellitus, i.e., glycated hemoglobin A1c (HbA1c) >10.0%. 9. Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2 10. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST), elevation > 3x the upper limit of normal (ULN), at screening confirmed by a repeat measurement at least 1 week apart. 11. Creatine kinase (CK) > 5x ULN without a known cause 12. Other serious comorbid disease in which the life expectancy of the subject is shorter than the duration of the trial (e.g., acute systemic infection or other serious illnesses). 13. Any history of malignant disease, with the exception of treated basal-cell carcinoma occurring >5 years before screening. 14. Females who are pregnant or nursing, or who are of childbearing potential (includes adolescent females who have reached menarche and are sexually active) and unwilling to use at least two methods of contraception (e.g., oral contraceptives, barrier methods, approved contraceptive implant, long- term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion: a. Women >2 years postmenopausal (defined as 1 year or longer since their last menstrual period) AND more than 55 years of age b. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of enrollment c. Women who are surgically sterilized at least 3 months prior to enrollment d. Adolescent females who have not reached menarche 15. Males who are unwilling to use an acceptable method of birth control during the entire study period (e.g., condom with spermicide). 16. Known history of alcohol and/or drug abuse within 5 years. 17. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to: a. Inappropriate for this study, including subjects who are unable to communicate or to cooperate with the investigator. b. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency). c. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study). d. Have any medical or surgical condition, which in the opinion of the investigator would put the subject at increased risk from participating in the study. e. Involved with, or a relative of, someone directly involved in the conduct of the study. 18. Any clinically significant disease or condition affecting a major organ system, including but not limited to gastrointestinal, renal, hepatic, endocrinologic, pulmonary, neurological, metabolic or cardiovascular disease. 19. Any surgical or medical condition which, in the judgment of the Investigator, might interfere with the pharmacokinetics, distribution, metabolism, or excretion of the study drug (if applicable). 20. Treatment with other investigational medicinal products or devices within 30 days or 5 half-lives, whichever is longer, prior to the administration of the study drug, planned use of investigational medicinal products or devices. 21. Previous participation in this study or any preceding study with ALN-PCSSC. 22. Hypersensitivity to any of the ingredients of the study drug being used. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percentage change in LDL-C. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The EOS visit and the last estimation of lipids will occur at Day 180. |
|
E.5.2 | Secondary end point(s) |
• Absolute change and percentage change in LDL-C • Absolute change and percentage change in PCSK9 levels • Absolute change and percentage change in other total cholesterol, triglycerides, HDL-C, non-HDL-C, VLDL-C, Apo-A1, Apo-B and Lp(a)
Exploratory Endpoint(s): • Anti-drug antibodies (ADA) to ALN-PCSSC • Response of LDL-C reduction by underlying causal mutations of HoFH |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Netherlands |
South Africa |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |